Wall Street analysts forecast that Trevena, Inc. (NASDAQ:TRVN – Get Rating) will post earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Trevena’s earnings. Trevena posted earnings of ($0.06) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 50%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Trevena will report full-year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.40) to ($0.32). For the next financial year, analysts forecast that the firm will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.36) to ($0.27). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Trevena.
Trevena (NASDAQ:TRVN – Get Rating) last announced its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. Trevena had a negative return on equity of 62.36% and a negative net margin of 7,771.74%. During the same quarter in the prior year, the company posted ($0.08) EPS.
Shares of TRVN opened at $0.26 on Monday. The business’s 50-day moving average is $0.42 and its two-hundred day moving average is $0.59. The company has a market capitalization of $43.04 million, a P/E ratio of -0.84 and a beta of 2.44. Trevena has a fifty-two week low of $0.26 and a fifty-two week high of $2.20.
Several hedge funds have recently bought and sold shares of TRVN. Geode Capital Management LLC lifted its stake in Trevena by 11.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,028,595 shares of the biopharmaceutical company’s stock valued at $3,725,000 after buying an additional 306,851 shares in the last quarter. SG Americas Securities LLC purchased a new position in Trevena in the 3rd quarter valued at about $103,000. Barclays PLC purchased a new position in Trevena in the 3rd quarter valued at about $83,000. State Board of Administration of Florida Retirement System purchased a new position in Trevena in the 3rd quarter valued at about $194,000. Finally, LPL Financial LLC lifted its stake in Trevena by 23.4% in the 4th quarter. LPL Financial LLC now owns 207,295 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 39,301 shares in the last quarter. 21.20% of the stock is currently owned by institutional investors and hedge funds.
About Trevena (Get Rating)
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
- Get a free copy of the StockNews.com research report on Trevena (TRVN)
- Littelfuse Stock is Hitting on All Cylinders
- Mattel Stock is Ready to Catch
- HCA Healthcare Stock is Ready to Climb Higher
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.